



**Maryland Prescription Drug Affordability Board**  
**Meeting Agenda**  
Virtual  
January 27, 2025 — 2:00 p.m.

- I. Call to Order
- II. Approve November 25, 2024 Meeting Minutes
- III. Opportunity for Public Comment<sup>1</sup>
- IV. Final Action- Amendments to COMAR 14.01.04.05 Cost Review Study
- V. Cost Review Study— Farxiga and Jardiance
  - a. Staff Presentation- Overview of Process
  - b. Closed Session—To Consult with Counsel and Receive Legal Advice, under GP § 3-305(b)(7), and to Consider and Discuss Confidential, Trade Secret and Proprietary Information, under GP § 3-305(b)(13) and HG 21-2c-03(e)(1)(iv) (Farxiga, Jardiance)
  - c. Staff Presentation on Data and Analyses
    - i. Farxiga
    - ii. Jardiance
  - d. Board Discussion of Farxiga and Jardiance
  - e. Preliminary Determination
- VI. Administrative Update
- VII. Adjournment

Please register for the Prescription Drug Affordability Board Meeting on January 27, 2025 at 2:00 PM ET at [pdab.maryland.gov](http://pdab.maryland.gov). After registering, you will receive a confirmation email containing information about how to join the webinar.

Next PDAB Meeting: The Board’s next regularly scheduled meeting will be on March 24, 2025.

Registration information for this meeting will be published on the PDAB website at [pdab.maryland.gov](http://pdab.maryland.gov).

---

<sup>1</sup> The public may submit written comments on the Board’s pending decisions, or general comments regarding the Board’s work, to [comments.pdab@maryland.gov](mailto:comments.pdab@maryland.gov). For more information on presenting comments during the meeting, please visit the Board Meetings page at the PDAB’s website.